{"id":"W4410821849","doi":"10.1200/jco.2025.43.16_suppl.4571","title":"EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Urothelial cancer; Oncology; Chemotherapy; Internal medicine; Subgroup analysis; Phases of clinical research; Cancer; Immunotherapy; Bladder cancer; Meta-analysis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00678807,0.001676973,0.002955116,0.0005300023,0.000358694,0.001187773,0.0009647163,0.001388154,0.003229163],"category_scores_gemma":[0.002809328,0.0005544744,0.006594859,0.0006135131,0.000652084,0.0009062592,0.0009618221,0.002422041,0.0005207557],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009013849,"about_ca_system_score_gemma":0.001329618,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007882921,"about_ca_topic_score_gemma":0.003556993,"domain_scores_codex":[0.9980946,0.001147307,0.0001314256,0.0002676603,0.0001390509,0.0002199024],"domain_scores_gemma":[0.9983505,0.0005339762,0.0003835625,0.0002904835,0.00008836614,0.0003532048],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9284276,0.002381098,0.01256863,0.001234023,0.02725805,0.0001320281,0.0001131854,0.001269863,0.006259819,0.00009805091,0.002183603,0.01807409],"study_design_scores_gemma":[0.5907816,0.2004708,0.1288521,0.0002473667,0.06434837,0.0005243057,0.0003095158,0.002793862,0.003152987,0.0009157336,0.007410368,0.0001929782],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9815893,0.009709012,0.0008707431,0.0004936408,0.0002510784,0.001446079,0.004454915,0.00008503391,0.001100166],"genre_scores_gemma":[0.9865725,0.001984915,0.0009711973,0.0008951079,0.0002202018,0.001826461,0.006248658,0.00005111011,0.001229872],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00678807,"threshold_uncertainty_score":0.03589922,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04983913750394723,"score_gpt":0.4465752331951335,"score_spread":0.3967360956911863,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}